Mereo BioPharma Group PLC ADR

Stock Chart, Company Information, and Scan Results

$0.24(as of May 8, 9:58 AM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Mereo BioPharma Group PLC ADR Company Information, Fundamentals, and Technical Indicators

Stock Price$0.24
Ticker SymbolMREO
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees39
CountyUSA
Market Cap$37.9M
EBIDTA-37.9M
10-Day Moving Average0.27
P/E Ratio-0.91
20-Day Moving Average0.30
Forward P/E Ratio0.00
50-Day Moving Average0.34
Earnings per Share-0.25
200-Day Moving Average1.21
Profit Margin-Infinity%
RSI29.67
Shares Outstanding159.6M
ATR0.03
52-Week High3.05
Volume2,787,953
52-Week Low0.20
Most Recent Support Level0.26
Book Value40.9M
Most Recent Resistance Level0.30
P/B Ratio0.94
Upper Keltner0.37
P/S Ratio76.52
Lower Keltner0.23
Debt-to-Equity Ratio0.37
Next Earnings DateUnknown
Cash Surplus36.7M
Next Ex-Dividend DateUnknown

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung disease; and Vantictumab, an anti-FZD monoclonal antibody for the treatment of autosomal dominant osteopetrosis type 2. It also develops Leflutrozole, an oral aromatase inhibitor, which is in Phase 2 trials for use in the treatment of hypogonadotropic hypogonadism; Navicixizumab, which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Etigilimab, an IgG1 monoclonal antibody which binds to the human TIGIT receptor on immune cells for the Treatment of advanced solid tumors; and Acumapimod, a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; and licensing agreement with AstraZeneca. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, United Kingdom.

Mereo BioPharma Group PLC ADR In Our Stock Scanner

As of May 08, 2026
example chart graphic
Scan Name: Low PB RatioScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Mean ReversionScan Type: Stock Indicator Scans
As of ---
example chart graphic
Scan Name: Most Active Penny Stocks Scan Type: Stock Indicator Scans
As of ---
example chart graphic
Scan Name: Long Legged DojiScan Type: Candlestick Pattern Scans
As of ---
example chart graphic
Scan Name: Doji CandlesScan Type: Candlestick Pattern Scans
As of ---
example chart graphic
Scan Name: Oversold Stocks Scan Type: Stock Indicator Scans
As of ---
example chart graphic
Scan Name: Low Debt to Equity RatioScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Unusual VolumeScan Type: Stock Indicator Scans
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.

This site uses cookies to provide you with an optimal user experience. By using StockMarketGuides.com, you accept our use of cookies.